Trials / No Longer Available
No Longer AvailableNCT04678479
Ganaxolone Expanded Access Program Compassionate Use
Expanded Access With Adjunctive Ganaxolone Treatment in Children and Young Adults With Cyclin Dependent Kinase-like 5 Deficiency Disorder
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Marinus Pharmaceuticals · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- —
Summary
The primary objective is to provide GNX to patients ≥ 2 years with CDD-related seizures who are refractory to, or intolerant of, standard therapy.
Detailed description
This is a multi-center, long-term, open-label, expanded access protocol of adjunctive GNX treatment in children, adolescents, and adults with CDD. Patients with inadequate seizure control on their current anti seizure medications at therapeutic doses will be eligible for enrollment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ganaxolone | ganaxolone |
Timeline
- First posted
- 2020-12-22
- Last updated
- 2024-01-22
Source: ClinicalTrials.gov record NCT04678479. Inclusion in this directory is not an endorsement.